- Clinical Trials
Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, REQORSA™ immunogene therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.
We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease.
Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline
Presentations to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes
Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes
Genprex’s lead drug candidate, REQORSA™ Immunogene Therapy that uses our proprietary, non-viral ONCOPREX® Nanoparticle Delivery System was highlighted in a Key Opinion Leader event hosted by Alliance Global Partners (AGP) for their institutional customers.
We’re passionate about the work we’re doing to revolutionize the fight against cancer and diabetes. Whether you or somebody you know is afflicted by one of these diseases, you are a medical practioner interested in our treatment options, or you are an investor that has supported our fight, we want to keep you informed of our advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.